2. Search Result
Search Result
Results for "

analgesia

" in MedChemExpress (MCE) Product Catalog:

77

Inhibitors & Agonists

22

Peptides

3

Natural
Products

1

Isotope-Labeled Compounds

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-106887
    SCH 32615

    		Others Neurological Disease
    SCH 32615 is an enkephalinase (the enzymes responsible for the degradation of endogenous enkephalins) inhibitor. SCH 32615 can enhance surgery- and pregnancy-induced analgesia in mice .
    SCH 32615
  • HY-119104
    AZD1940

    		Cannabinoid Receptor Neurological Disease
    AZD1940 is an orally active, high affinity cannabinoid CB1/CB2 receptor agonist with pKi values of 7.93 and 9.06 for human CB1R and CB2R, respectively. AZD1940 shows a robust analgesia action .
    AZD1940
  • HY-118120
    GEMSA

    2-Guanidinoethylmercaptosuccinic acid

    		 Others Neurological Disease
    GEMSA is a potent inhibitor of enkephalin convertase (Ki=8.8 nM). GEMSA elicites analgesia .
    GEMSA
  • HY-163917
    SalA-VS-08

    		Opioid Receptor Neurological Disease
    SalA-VS-08 is a full agonist of kappa-opioid receptor (KOR) with selectivity and G-protein bias. SalA-VS-08 can be used in the research of analgesia .
    SalA-VS-08
  • HY-W000665
    2,6-Dimethyl-L-tyrosine

    Dmt

    		 Opioid Receptor Neurological Disease
    2,6-Dimethyl-L-tyrosine (Dmt) is a tyrosine derivative that enhances receptor affinity, functional bioactivity and in vivo analgesia of opioid peptides .
    2,6-Dimethyl-L-tyrosine
  • HY-P3087
    Tyr-W-MIF-1

    		Opioid Receptor Neurological Disease
    Tyr-W-MIF-1 is an opioid tetrapeptide with opiate and antiopiate activity. Tyr-W-MIF-1 can induce analgesia .
    Tyr-W-MIF-1
  • HY-P2199
    SNF 9007

    		Opioid Receptor Neurological Disease
    SNF 9007 is a cholecystokinin analog. SNF 9007 induces analgesia by acting on δ-1, δ-2, and μ opioid receptors in the mouse brain .
    SNF 9007
  • HY-P5892
    β-Endorphin (1-27) (human)

    		Opioid Receptor Neurological Disease
    β-Endorphin (1-27) (human) is an opioid antagonist that binds μ-, δ-, and κ-opioid receptors with Kis of 5.31, 6.17, and 39.82 nM, respectively. β-Endorphin (1-27) (human) inhibits β-Endorphin (HY-P1502)-induced and etorphine-induced analgesia .
    β-Endorphin (1-27) (human)
  • HY-120769
    Pimprinine

    		Monoamine Oxidase Neurological Disease Inflammation/Immunology
    Pimprinine is a potent monoamine oxidase inhibitor, could be isolated from fermented broths. Pimprinine has antioxidative activity and anticonvulsant activity. Pimprinine inhibits tremorine-induced tremors and analgesia in mice .
    Pimprinine
  • HY-115823
    ztz240

    		Potassium Channel Neurological Disease
    ztz240 is a chemical modulator of voltage-gated potassium channel Kv7 (KCNQ) (KCNQ2 and 3: EC50=6.1 μM; KCNQ4: EC50=12.2 μM). ztz240 can be used in analgesia and anti-epileptic research .
    ztz240
  • HY-107527
    Org 25543 hydrochloride

    		GlyT Neurological Disease
    Org 25543 hydrochloride is a selective and irreversible GlyT2 inhibitor (IC50: 16 nM). Org 25543 hydrochloride has analgesia effect. Org 25543 hydrochloride ameliorates mechanical allodynia after partial sciatic nerve ligation injury in mice .
    Org 25543 hydrochloride
  • HY-17034A
    Dexmedetomidine hydrochloride
    Maximum Cited Publications
    10 Publications Verification

    (+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride

    		 Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine hydrochloride
  • HY-12719
    Dexmedetomidine
    Maximum Cited Publications
    10 Publications Verification

    (+)-Medetomidine; (S)-Medetomidine

    		 Adrenergic Receptor Neurological Disease Cancer
    Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine
  • HY-P2046
    β-Endorphin (rat)

    		Opioid Receptor Neurological Disease
    β-Endorphin (rat) is an endogenous opioid neuropeptide and peptide hormone. β-Endorphin (rat) has analgesic activity and also contributes to food intake in satiated rats. β-Endorphin (rat) can be used in the research of neurological diseases such as analgesia and drug addiction .
    β-Endorphin (rat)
  • HY-119990
    Fotocaine

    		Others Neurological Disease Inflammation/Immunology
    Fotocaine is a photochromic blocker of voltage-gated ion channels. Fotocaine is readily taken up by neurons in brain slices and enables optical control of action potential firing by switching between 350 and 450 nm light. Fotocaine can be used in analgesia research .
    Fotocaine
  • HY-106840
    L-365260
    1 Publications Verification

    		 Cholecystokinin Receptor Neurological Disease Metabolic Disease
    L-365260 is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with Kis of 1.9 nM and 2.0 nM, respectively. L-365260 interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors. L-365260 can enhance Morphine analgesia and prevents Morphine tolerance .
    L-365260
  • HY-153935
    EP4-IN-1

    		Prostaglandin Receptor Inflammation/Immunology Cancer
    EP4-IN-1 is a potent prostanoid EP4 receptor inhibitor. EP4-IN-1 is extracted from patent WO2023025270 (example 1), and exhibits prospect in tumor immunity and anti-inflammatory analgesia research .
    EP4-IN-1
  • HY-12719R
    Dexmedetomidine (Standard)

    		Adrenergic Receptor Neurological Disease Cancer
    Dexmedetomidine (Standard) is the analytical standard of Dexmedetomidine. This product is intended for research and analytical applications. Dexmedetomidine ((+)-Medetomidine) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine (Standard)
  • HY-P1338
    PL-017

    		Opioid Receptor Neurological Disease
    PL-017 is a potent and selective μ opioid receptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 produces long-lasting, reversible analgesia in rats .
    PL-017
  • HY-107743
    Naloxone benzoylhydrazone

    NalBzoH

    		 Opioid Receptor Neurological Disease
    Naloxone benzoylhydrazone (NalBzoH) is a mixed agonist/antagonist. Naloxone benzoylhydrazone is a prototypic κ3-opioid receptor agonist, and a partial agonist at the cloned μ and δ opioid receptors, and an antagonist at opioid-like NOP receptors. Naloxone benzoylhydrazone has potently analgesia effect .
    Naloxone benzoylhydrazone
  • HY-P1338A
    PL-017 TFA

    		Opioid Receptor Neurological Disease
    PL-017 TFA is a potent and selective μ opioid receptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 TFA produces long-lasting, reversible analgesia in rats .
    PL-017 TFA
  • HY-161812
    MOR agonist-4

    		Opioid Receptor Others
    MOR agonist-4 (2d) is a G protein signaling-biased Kappa opioid receptor (KOR) agonist with an EC50 value of 11 nM. MOR agonist-4 contains an electron withdrawing CF3 group and a bias factor of 38 based on triazole. MOR agonist-4 is used in the research of pruritis and analgesia .
    MOR agonist-4
  • HY-19057
    Vatinoxan

    MK-467; L-659066

    		 Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Vatinoxan (MK-467) is an alpha 2-adrenergic receptor antagonist. The peripheral selectivity of Vatinoxan determines that it has limited penetration across the blood-brain barrier and therefore has low concentrations in the central nervous system. Vatinoxan antagonizes alpha 2-adrenergic receptor receptors by binding to them, thereby reducing or preventing cardiovascular effects caused by α2-adrenergic agonists. Vatinoxan can be used in studies of cardiovascular effects, sedation and analgesia .
    Vatinoxan
  • HY-121483
    Leucinal

    		Others Others
    Leucinal is a competitive inhibitor of brain aminopeptidase, inhibits brain soluble aminopeptidase activity (Ki = 22 microM), and can enhance the analgesia induced by leuprorelin, but has no effect on the analgesia induced by some other substances.
    Leucinal
  • HY-163855
    KGP-25

    		Sodium Channel GABA Receptor Neurological Disease
    KGP-25 is an inhibitor of voltage-gated sodium channel 1.8 (Nav1.8), which can be used for analgesia by targeting Nav1.8 in the peripheral nervous system (PNS). KGP-25 can also target γ-aminobutyric acid subtype A receptor (GABAA) in the central nervous system (CNS) for general anesthesia .
    KGP-25
  • HY-129668
    Bremazocine

    		Adrenergic Receptor Neurological Disease
    Bremazocine is a potent opioid kappa receptor agonist with analgesic activity. Bremazocine induces peripheral analgesia by releasing endogenous norepinephrine. The analgesic effect of bremazocine is associated with interaction with adenosine receptors. Bremazocine produces a dose-dependent peripheral analgesia after topical application. The effect of bremazocine is affected by nonselective α(2) adrenaline receptor antagonists, suggesting that it acts through a norepinephrine pathway .
    Bremazocine
  • HY-107664A
    SR 142948 dihydrochloride

    		Neurotensin Receptor Neurological Disease
    SR 142948 dihydrochloride is an orally active and selective non-peptide neurotensin receptor (NT) antagonist with IC50s of 1.19 nM, 0.32 nM, 3.96 nM in h-NTR1-CHO cells, HT-29 cells, and adult rat brain, respectively. SR 142948 dihydrochloride antagonizes NT-induced inositol monophosphate formation in HT-29 cells with an IC50 of 3.9 nM. SR 142948 dihydrochloride blocks hypothermia, analgesia and steering behavior induced by NT in vivo. SR 142948 dihydrochloride shows blood-brain permeability and can be used in study of psychiatric disorders .
    SR 142948 dihydrochloride
  • HY-P5899
    Mambalgin-3

    		Sodium Channel Neurological Disease
    Mambalgin-3 is an acid-sensitive ion channel 1 (ASIC1) inhibitor. Mambalgin-3 can be used in the study of analgesia .
    Mambalgin-3
  • HY-P10394
    DP32

    		Opioid Receptor Neuropeptide FF Receptor Neurological Disease
    DP32 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP32 can be used in analgesia-related research .
    DP32
  • HY-P10395
    DP50

    		Opioid Receptor Neuropeptide FF Receptor Neurological Disease
    DP50 is a bifunctional compound that contains an opioid receptor (MOP) agonist and a neuropeptide FF receptor (NPFFR) antagonist. DP50 can be used in analgesia-related research .
    DP50
  • HY-P1198
    Hemokinin 1, human

    		Neurokinin Receptor Neurological Disease
    Hemokinin 1, human is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human can produces an opioid-independent analgesia .
    Hemokinin 1, human
  • HY-N6891
    Hamaudol
    1 Publications Verification

    		 COX Inflammation/Immunology
    Hamaudol is a chromone isolated from Saposhnikovia divaricata. Hamaudol shows significant inhibitory activity on cyclooxygenase (COX)-1 and COX-2 activities with IC50 values of 0.30, 0.57 mM, respectively, and has potent analgesia and anti-inflammary effects .
    Hamaudol
  • HY-105651A
    Butalamine hydrochloride

    		Others Cardiovascular Disease
    Butalamine (hydrochloride) is a peripheral vasodilator with local anesthetic effects. :Butalamine (hydrochloride) can produce in animals coronary vasodilation, local anaesthesia, analgesia and a papaverine like action in duodenal preparations. Butalamine (hydrochloride) causes a slowing in rate of spontaneous activity, a decrease in amplitude and a reduction in isolated human smooth muscle .
    Butalamine hydrochloride
  • HY-P1198A
    Hemokinin 1, human TFA

    		Neurokinin Receptor Neurological Disease
    Hemokinin 1, human TFA is a selective tachykinin neurokinin 1 (NK1) receptor full agonist. Hemokinin 1, human TFA is a full agonist at NK2 and NK3 receptor. Hemokinin 1, human TFA can produces an opioid-independent analgesia .
    Hemokinin 1, human TFA
  • HY-B0718
    Methoxyflurane

    DA-759

    		 Potassium Channel Neurological Disease
    Methoxyflurane disrupts neuronal transmission by interfering with the release and re-uptake of neurotransmitters at post-synaptic terminals, or altering ionic conductance following receptor activation[1]. Methoxyflurane is an analgesic agent that provides rapid short-term analgesia. Methoxyflurane may shows a effective non-opioid treatment option for trauma pain .
    Methoxyflurane
  • HY-B1288A
    Oxybuprocaine

    Benoxinate; Novesinol; Oxybucaine

    		 Others Inflammation/Immunology
    Oxybuprocaine is a short-acting ester-type local anesthetic agent used in ophthalmology and otolaryngology .
    Oxybuprocaine
  • HY-163669
    ITI-333

    		Others Neurological Disease
    ITI-333 is a tetracyclic compound with oral bioavailability and analgesic activity, targeting multiple receptors. ITI-333 can be used for research on various forms of pain .
    ITI-333
  • HY-P10555
    (D-Arg2, Sar 4)-Dermorphin (1-4)

    		Opioid Receptor Neurological Disease
    (D-Arg2, Sar 4)-Dermorphin (1-4) is a tetrapeptide derivative of the peptide Dermorphin (HY-P0244) found in amphibian skin. (D-Arg2, Sar 4)-Dermorphin (1-4) has significant analgesic effects by binding to the μ-opioid receptor (MOR) in the body. (D-Arg2, Sar 4)-Dermorphin (1-4) can be used in the development of analgesic drugs .
    (D-Arg2, Sar 4)-Dermorphin (1-4)
  • HY-129237
    Azo-enkephalin

    		Others Neurological Disease
    Azo-enkephalin is an endorphin analog with significant analgesic activity. Azo-enkephalin can be used in the development of opioid analgesics .
    Azo-enkephalin
  • HY-15691A
    PF-4455242 hydrochloride

    		Others Inflammation/Immunology
    PF-4455242 hydrochloride is a selective, short-acting antagonist of the κ-opioid receptor, exhibiting potential analgesic effects. PF-4455242 hydrochloride has been identified through a strategy utilizing parallel chemistry and physicochemical property design. PF-4455242 hydrochloride demonstrated confirmed potency and selectivity in the tail-flick analgesia model.
    PF-4455242 hydrochloride
  • HY-138232
    Lys-psi(CH2NH)-Trp(Nps)-OMe

    LTNAM

    		 Others Neurological Disease
    Lys-psi(CH2NH)-Trp(Nps)-OMe is a lysine-tryptophan (Nps) pseudodipeptide analog. It is obtained by replacing the peptide bond in the Lys-Trp(Nps) molecule with an aminomethylene bond and has analgesic activity. Lys-psi(CH2NH)-Trp(Nps)-OMe induces a dose-dependent and naloxone-reversible analgesia after intracerebroventricular administration in mice, and its analgesic effect lasts longer than that of the original compound. It protects methionine enkephalin from degradation in rat striatal slices and binds to low-dose opioid peptides to produce analgesia. Lys-psi(CH2NH)-Trp(Nps)-OMe effectively inhibits brain aminopeptidase activity both in vitro and in vivo. The enhanced resistance of this pseudodipeptide to proteolysis may explain its prolonged analgesic activity.
    Lys-psi(CH2NH)-Trp(Nps)-OMe
  • HY-131019
    JF-NP-26

    		mGluR Neurological Disease
    JF-NP-26, an inactive photocaged derivative of raseglurant, is the first caged mGlu5 receptor negative allosteric modulator. Uncaging of JF-NP-26 is elicited with light pulses in the visible spectrum (405 nm). JF-NP-26 induces light-dependent analgesia in models of inflammatory and neuropathic pain in freely behaving animals .
    JF-NP-26
  • HY-121974
    SR14150

    		Others Neurological Disease
    SR14150 is a partial agonist of the NOP receptor with high affinity. The biological activity of SR14150 makes it potentially useful for the development of a new generation of multi-target opioids designed to simultaneously improve analgesia and reduce side effects. The activity of SR14150 and its interaction with other opioid receptors may provide new inhibitory options for the management of chronic pain .
    SR14150
  • HY-15249
    JZL 184
    3 Publications Verification

    		 MAGL Neurological Disease
    JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC50 of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH .
    JZL 184
  • HY-108707
    LY3130481
    1 Publications Verification

    		 iGluR Neurological Disease
    LY3130481 is an orally available AMPA receptor antagonist, selectively inhibiting the IC50 value of AMPA/TARP γ-8 at 65 nM. LY3130481 has anticonvulsant, antiepileptic, and pain-relieving effects .
    LY3130481
  • HY-106840A
    L-365260 hemihydrate
    1 Publications Verification

    		 Cholecystokinin Receptor Neurological Disease Metabolic Disease
    L-365260 hemihydrate is an orally active and selective antagonist of non-peptide gastrin and brain cholecystokinin receptor (CCK-B), with Kis of 1.9 nM and 2.0 nM, respectively. L-365260 hemihydrate interacts in a stereoselective and competitive manner with guinea pig stomach gastrin and brain CCK receptors .
    L-365260 hemihydrate
  • HY-132219
    N,N-Dipropyldopamine hydrobromide

    		Others Cancer
    N. N-dipropyrldopamine is a potent inhibitor of glutamate release and has anticancer activity. The increase of glutamate secretion leads to cancer-induced bone pain (CIBP). N. N-dipropyrldopamine plays an analgesic role in CIBP .
    N,N-Dipropyldopamine hydrobromide
  • HY-118756
    Anirolac

    RS37326

    		 Endogenous Metabolite Inflammation/Immunology
    Anirolac (RS37326) is a nonsteroidal anti-inflammatory agent with analgesic activity. Anirolac showed analgesic efficacy comparable to that of naproxen in suppressing moderate or severe postpartum uterine pain. Anirolac induced significantly higher analgesia scores than placebo within 6 hours, especially at the 100 mg dose. Anirolac effectively relieved pain and showed a stronger analgesic effect than placebo in every assessment .
    Anirolac
  • HY-17034AR
    Dexmedetomidine hydrochloride (Standard)

    (+)-Medetomidine hydrochloride (Standard); (S)-Medetomidine hydrochloride (Standard)

    		 Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Dexmedetomidine (hydrochloride) (Standard) is the analytical standard of Dexmedetomidine (hydrochloride). This product is intended for research and analytical applications. Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects .
    Dexmedetomidine hydrochloride (Standard)
  • HY-17034AS
    Dexmedetomidine-13C,d3 hydrochloride

    (+)-Medetomidine-13C,d3 hydrochloride; (S)-Medetomidine-13C,d3 hydrochloride

    		 Isotope-Labeled Compounds Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Dexmedetomidine- 13C,d3 (hydrochloride) is the 13C- and deuterium labeled Dexmedetomidine (hydrochloride). Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects[1][2][3].
    Dexmedetomidine-13C,d3 hydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: